-
Sell-Side Positive On Johnson & Johnson's Unexpected Ohio Opioid Settlement
Wednesday, October 2, 2019 - 3:06pm | 708Read More...Johnson & Johnson (NYSE: JNJ) announced a $20.4-million agreement Wednesday with the Ohio counties of Cuyahoga and Summit to settle an opioid lawsuit with the state, removing the company from federal multidistrict litigation. The Analysts Credit Suisse analyst Matt Miksic reiterated an...
-
Focus On Abbott Labs Remains On Pending Deals
Thursday, July 21, 2016 - 2:28pm | 325Read More...Qualifying the second quarter results of Abbott Laboratories (NYSE: ABT) as solid, UBS indicated the focus of investors is now on the pending deals with Alere Inc (NYSE: ALR) and St. Jude Medical, Inc. (NYSE: STJ). Investors seek clarity on whether and when these deals will be consummated. UBS...
-
Mylan Shares Still Not Getting Enough Respect; UBS Likes News Of Expansion Into Tropicals
Monday, May 16, 2016 - 4:45pm | 171Read More...UBS' Matt Miksic expressed his enthusiasm for Mylan Inc. (NASDAQ: MYL) after the company announced its plans to acquire Renaissance's Tropical/Generics for $950 in cash. "The manufacturing facilities and dermatologist sales force (we estimate 50-100 reps) add an important...
-
UBS: Baxalta Is A Buy Even If Shire Buyout Doesn't Happen
Monday, January 4, 2016 - 6:15pm | 252Read More...Baxalta Inc (NYSE: BXLT) shares had a big Monday after a Bloomberg report of acquisition interest from Shire PLC (ADR) (NASDAQ: SHPG) hit wires over the weekend. According to the report, Shire is in advanced talks to buy Baxalta for about $32 billion in cash and stock excluding debt -- a per...
-
UPDATE: Piper Jaffray Reiterates on LDR Holding Following Solid Top- and Bottom-Line Beat
Thursday, November 7, 2013 - 12:51pm | 188Read More...In a report published Thursday, Piper Jaffray analyst Matt Miksic reiterated an Overweight rating on LDR Holding (NASDAQ: LDRH), and raised the price target from $26.00 to $27.00. In the report, Piper Jaffray noted, “After successfully completing its IPO on October 8, management delivered a very...
-
UPDATE: Piper Jaffray Initiates Coverage on LDR Holding on Unique High-Growth, High-Value Portfolio
Monday, November 4, 2013 - 12:06pm | 192Read More...In a report published Monday, Piper Jaffray analyst Matt Miksic initiated coverage on LDR Holding Corporation (NASDAQ: LDRH) with an Overweight rating and $26.00 price target. In the report, Piper Jaffray noted, “LDR's portfolio of patent-protected and PMA-supported products is a high-growth, high...
-
UPDATE: Piper Jaffray Upgrades Integra LifeSciences On FDA Inspection Results
Thursday, August 15, 2013 - 7:56am | 173Read More...In a report published on Thursday, Piper Jaffray analyst Matt Miksic upgraded Integra LifeSciences (NASDAQ: IART) from Neutral to Overweight and raised the price target on the company from $41 to $50. In the report, Piper Jaffray stated, "We view the completion of the FDA's recent inspection of...
-
UPDATE: Piper Jaffray Reiterates Overweight on Globus Medical on Synthes Award in Line With Expectations
Monday, June 17, 2013 - 3:33pm | 202Read More...In a report published on Monday, Piper Jaffray analyst Matt Miksic reiterated an Overweight rating on Globus Medical (NYSE: GMED) and maintained a $22 price target on the company. In the report, Piper Jaffray commented that, "The jury award related to the Synthes patent case was roughly in line...
-
UPDATE: Piper Jaffray Lowers PT on TranS1 Following Updated Projections
Wednesday, May 29, 2013 - 10:12am | 196Read More...In a report published Wednesday, Piper Jaffray analyst Matt Miksic reiterated an Overweight rating on TranS1 (NASDAQ: TSON), but lowered the price target from $4.00 to $3.00. In the report, Piper Jaffray noted, “We are updating our projections for TSON and trimming our 12-month target. After...
-
PiperJaffray Lowers NuVasive (NUVA) Price Target, Reiterates Overweight Rating
Friday, February 26, 2010 - 10:56am | 141Read More...PiperJaffray analysts Matt Miksic and Roshni Sacks reiterated their Overweight rating for shares of NuVasive, Inc. (Nasdaq: NUVA) and lowered their price target from $55 to $47. The analysts noted that, "the company's reclassification of certain operating expenses, unveiled a level of gross profit...
